Next, we took advantage of SASP, the chemical inhibitor specific for xCT, which had been widely used to disrupt xCT functions previously [18, 19], to determine if the beneficial effects of xCT deficiency could be translated into clinical application against TB. This evidence concerns the gene SLC7A11 and tuberculosis.